Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery

Abstract

Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab) paclitaxel (nab-paclitaxel; Abraxane) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nab-technology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

“…In fact, currently there is only one polymeric nanoparticle available in the market, Abraxane (ABI-007), an albumin-bound paclitaxel nanoparticle that was approved by the FDA [18,197,420,421] 3 First nanoparticle to enter in clinical trials. 4 PSMA: prostate-specific membrane antigen.…”

Preparation, characterization, and antitumor activities of folate-decorated docetaxel-loaded human serum albumin nanoparticles

“…These properties, as well as preferential uptake (passive targeting) in tumor tissue through enhanced permeation and retention (EPR) effect, non-covalent binding characteristics, ready availability, stability, and lack of toxicity and immunogenicity make human albumin an ideal candidate for drug delivery (Lin et al, 1993;Fu et al, 2009). …”

Synthesis of Polyester Nanoparticles in Miniemulsion Obtained by Radical Ring‐Opening of BMDO and Their Potential as Biodegradable Drug Carriers

“…Such formulations have a high allergic potential and may cause serious side effects such as nephrotoxicity, neurotoxicity, and cardiotoxicity, [16] and can also mediate neutropenia. [17] Another commercially available drug formulation of paclitaxel is nanoparticle albumin-bound (nab) paclitaxel [17] and has been approved for use in humans. Paclitaxel is absorbed to the hydrophobic pockets/binding sites of albumin.…”